Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.3/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 73.8; sample size: 20.0; recency: 90.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.8; sample size: 20.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.8; sample size: 20.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.8; sample size: 20.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 28.8; sample size: 20.0; recency: 90.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 31.2; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 61.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 66.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 26.2; sample size: 30.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 31.2; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 26.2; sample size: 30.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 60.2/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 73.7; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
